- BT1718 progressing in Cancer Research UK sponsored Phase IIa clinical trial
- Phase I trial of BT5528 currently dosing within predicted therapeutic range; preliminary signs of anti-tumor activity observed, including a partial response
- BT8009 pharmacokinetic profile consistent with preclinical predictions based on early clinical data; first clinical site outside the United States expected to open for recruitment this quarter
- BT7480 on track for Phase I trial start in 2H ’21; early immuno-oncology discovery has resulted in new programs targeting natural killer cells, which are now moving into lead optimization
https://finance.yahoo.com/news/bicycle-therapeutics-announces-pipeline-progress-120000421.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.